Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

← Back to all medicines

Asacol 800mg MR Tablets

⚠ This medicine appears to have been discontinued

The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.

If you were prescribed this medicine, other products containing Mesalazine may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.

Active substance: Mesalazine

Equivalent medicines (same active substance, strength and form)

Source: electronic medicines compendium (emc)
Official leaflet: Read the PIL on emc

What it is and what it is used for

for Asacol 800mg MR tablets contain the active substance mesalazine (also known as 5aminosalicylic acid) which is an anti-inflammatory drug used in the treatment of:

  • Ulcerative colitis – a disease of the large bowel (colon) and back passage (rectum) in which the lining of the bowel becomes inflamed (red and swollen). Symptoms can include rectal bleeding, frequent diarrhoea and abdominal pain. Asacol 800mg MR tablets act locally in the colon to reduce inflammation and can also prevent further episodes (flares) of ulcerative colitis.
  • Crohn's ileo-colitis – a disease affecting the small bowel (terminal ileum) and colon in which the lining of the bowel becomes swollen and sore. This may lead to the development of ulcers, abscesses and narrowing (strictures) in the bowel. Asacol 800mg MR tablets act locally in the terminal ileum and colon to control the disease and prevent further flares of Crohn's ileo-colitis.

What you need to know before you take it

e Asacol 800mg MR tablets Do not take the Asacol 800mg MR tablets if you:

  • are allergic to any of the ingredients in the product (see Section 6).
  • are allergic to aspirin or any other salicylate medicine.
  • had kidney problems or blood problems while taking other medicines such as sulphasalazine.
  • have confirmed severe kidney or liver problems.
  • have stomach ulcers, with or without bleeding. DO NOT give the tablets to children unless directed by a doctor.

Warnings and precautions Talk to your doctor before taking Asacol 800mg MR tablets if you have any medical conditions or illnesses. Tell your doctor if you have:

  • ever had any problems with your liver or kidneys, especially if you are elderly.
  • suffered an allergy to the medicine sulfasalazine in the past.
  • ever had allergic reactions of your heart such as inflammation of the heart muscle or heart sac. If you have had previous allergic reactions of your heart from mesalazine, then do not take Asacol 800mg MR tablets. Asacol 800mg MR tablets can be taken with care if you have had a previous allergic reaction of the heart even if not caused by taking mesalazine.
  • ever developed a severe skin rash or skin peeling, blistering and/or mouth ulcers after using mesalazine
  • if you experience strong or recurrent headache, disturbed vision, or ringing or buzzing in the ears contact your doctor immediately. Serious skin reactions have been seen with mesalazine treatment. If you notice any symptoms of a skin reaction (listed in Section 4), stop taking Asacol and seek medical help immediately. Asacol can cause red-brown urine in the toilet water. The colour change happens because of a reaction between mesalazine and bleach, but it doesn't harm you. Taking other medicines Please tell your doctor if you are taking or have recently taken any other medicines, including those obtained without a prescription (over-the-counter). Tell your doctor if you use any of the following:
  • medicines that affect the immune system such as azathioprine, 6-mercaptopurine or thioguanine
  • medicines that prevent the formation of blood clots, such as warfarin. Asacol 800mg MR tablets should NOT be taken with Lactulose, a medicine for constipation. Certain medicines can increase the risk of kidney reactions. These include:
  • non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, aspirin, or naproxen.
  • azathioprine, a medicine that weakens the immune system. Pregnancy and breast-feeding Women who are pregnant or breast-feeding should not take Asacol 800mg MR tablets unless advised otherwise by their doctor. Ask your doctor or pharmacist for advice before taking any medicine. Tests on your liver, kidney and blood Before you start treatment with Asacol 800mg tablets you will have a blood and urine test to check how well your kidneys are working and what your blood is doing. During treatment your doctor will check how well your liver, kidney and blood is working by taking blood and urine sample.

Kidney stones may develop with use of mesalazine. Kidney stones are hard lumps that can cause pain in your sides and blood in your urine. Take care to drink enough liquid during treatment with mesalazine. This can help prevent kidney stones from developing. Driving and using machines Asacol 800mg MR tablets are not expected to affect your ability to drive or operate machinery. Important information about some of the ingredients of Asacol 800mg MR tablets

  • Lactose (a type of sugar contained in milk). This medicine contains a small amount of lactose. If you know you have an intolerance to some sugars, contact your doctor before taking this medicine. •

Sodium (salt). This medicine contains less than 1 mmol (23 mg) sodium per dosage unit, i.e. is essentially "sodium-free".

How to take it

Asacol 800mg MR tablets Always take Asacol 800mg MR tablets exactly as your doctor has told you. You should check with your doctor if you are not sure. The tablets should be swallowed whole with water. Do not break, crush or chew the tablet. You can take them at any time of the day, with or without meals. While taking this medicine, make sure you drink enough fluids to stay hydrated. This is especially important if you have been vomiting, having diarrhoea, have a high fever or heavy sweating. This will help avoid problems with your kidneys. Recommended dose:

  • Treating ulcerative colitis – up to 6 tablets each day divided throughout the day (as advised by your doctor).
  • Preventing a flare of ulcerative colitis – up to 3 tablets each day once daily or divided throughout the day (as advised by your doctor).
  • Preventing a flare of Crohn's ileo-colitis – up to 3 tablets each day divided throughout the day (as advised by your doctor). DO NOT take more than 6 tablets a day. Asacol 800mg MR tablets are not recommended for use in children. If you stop taking Asacol 800mg MR tablets Keep taking the 800mg MR tablets for as long as your doctor tells you. Your symptoms may come back if you stop treatment too early. Remember to get a repeat prescription at the right time so that you do not miss a day of treatment. If you take more Asacol 800mg MR tablets than you should Do not take more than the recommended dose. You should only take as many tablets as your doctor has instructed on the pharmacist's label. If you take too much medicine, tell your doctor immediately or go to your nearest Accident & Emergency Department. Take the tablet pack with you if possible.

If you forget to take Asacol 800mg MR tablets If you forget to take a dose at the required time, take it as soon as you remember and continue taking your tablets as before. DO NOT take two doses together. If it is almost time for your next dose, wait until then and carry on as before. If you have any further questions on the use of this product, ask your doctor or pharmacist. 4. Possible side effects Like all medicines, Asacol 800mg MR tablets can cause side effects, although not everybody gets them. A drug allergy is a reaction your body has to a medicine. Allergic reactions can happen after taking Asacol. Tell your doctor if you have any of these symptoms:

  • Rash with or without itching,
  • Shortness of breath,
  • Rapid heartbeat,
  • Chest pain. These effects will usually disappear when you stop taking the medicine. Tell your doctor immediately if you have any of the following:
  • Fever, sore throat, mouth or lip ulcers, spots underneath the skin anywhere on your body, including the genital and anal area
  • Become very pale
  • Swollen ankles
  • Have unusual bleeding (such as unexpected nosebleeds or bleeding gums)
  • Skin rash with flaking, boils or sore lips or mouth
  • Bruising more easily or blood problems
  • Problems with how the kidney works, such as a change in the colour or amount of urine produced and swollen limbs or a sudden flank pain (caused by a kidney stone)
  • Symptoms such as cramping, severe stomach pain, bloody and excessive stools (diarrhoea), fever, headache or rash. These symptoms could be a sign of Acute Intolerance Syndrome. It can happen during a sudden episode of ulcerative colitis. This is a serious and rare condition and would require you to stop treatment immediately.
  • If you experience strong or recurrent headache, disturbed vision, or ringing or buzzing in the ears. These could be symptoms of increased pressure within your skull (idiopathic intracranial hypertension). Stop using mesalazine and seek medical attention immediately if you notice any of the following symptoms of a serious skin rash:
  • Reddish patches on the body that look like targets or circles. These patches might have blisters in the middle and your skin could peel. You may also have ulcers in your mouth, throat, nose, genitals and eyes. This rash can spread all over your body and you might have a fever and other flu-like symptoms (body aches, tiredness). Common side effects (may affect more than 1 in 100 people but less than 1 in 10 people):
  • Diarrhoea
  • Stomach pain
  • Vomiting
  • Nausea (feeling sick)
  • Wind
  • Headache
  • Joint and muscle pain
  • Indigestion
  • Rectal disorder (issues around the rectum, the part of the body where stool is held and then leaves the body). Rare side effects (may affect less than 1 in 1,000 people):
  • Problems with heart (including inflammation of the heart muscles and associated structures)
  • Problems with liver (including inflammation of liver, liver failure, or abnormal liver tests)
  • Problems with lung [including eosinophilic pneumonia (a lung disease where certain white blood cells increase in the lungs and bloodstream), bronchospasm (breathing difficulty caused by narrowed airways), unexplained wheezing or shortness of breath]
  • Problems with kidney [including inflammation, scarring, or kidney failure, (which may go away if treatment is stopped early)]
  • Inflammation of the pancreas, an organ involved in digestion
  • Problems with blood (including a decrease in the number of white blood cells (help fight infection), red blood cells (carry oxygen to the body) and/or platelets (help stop bleeding)
  • Numbness and tingling of the fingers and toes caused by nerve damage,
  • Feeling dizzy or experiencing a spinning sensation (vertigo)
  • Chest pain or chest infections
  • Sinusitis (inflammation of the sinuses, which can cause pain and pressure in the face)
  • Rhinitis (inflammation of the lining of the nose, which can cause a runny or stuffy nose)
  • Skin rashes
  • Skin blisters filled with fluid.
  • Hair loss
  • Cough
  • Drug fever (having a fever while taking the medicine, which goes away when the medicine is stopped)
  • Flu like symptoms such as body aches and tiredness
  • Lupus, a long-term disease that can cause swelling and pain in any part of the body. Very rare side effects (may affect less than 1 in 10,000 people):
  • Symptoms of colitis get worse
  • Erythema multiforme (skin disorder that can cause redness and rashes).
  • Lung scarring (tissue in the lungs becomes thick and stiff, making it hard to breathe)
  • Temporary decrease in sperm count that returns to normal when the medicine is stopped Not known (frequency cannot be estimated from available data)
  • Allergic reactions
  • Constipation

• • • • •

Lung disease (allergic reactions and diseases which can cause difficulty breathing, chest pain, and dry cough) Kidney stones and pain in your sides (see also Section 2). Increased pressure within your skull (idiopathic intracranial hypertension), symptoms of which could be strong or recurrent headache, disturbed vision, or ringing or buzzing in the ears. Serious illness with blistering of the skin. These blisters can lead to skin peeling and result in painful, raw areas. This condition can also affect your mouth, eyes and genitals. Issues tolerating mesalazine. This can make your existing condition worse, causing severe diarrhoea and abdominal pain.

Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any

Possible side effects

not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.

How to store it

ASACOL 800MG MR TABLETS Keep out of the sight and reach of children. Please keep the moisture absorbing pouch in the bottle. The pouch is not part of your medicine and is marked DO NOT EAT. Keep the bottle tightly closed. Do not use Asacol 800mg MR tablets after the expiry date which is stated on the pack after 'Exp'. The expiry date refers to the last day of that month. Medicines should not be disposed in wastewater or household waste. Ask your pharmacist how to dispose of medicines you no longer need. This will help protect the environment.

Contents of the pack and other information

What Asacol 800mg MR tablets contain The active substance is mesalazine. Each tablet contains 800 mg of mesalazine.

  • Other ingredients inside the medicine core: lactose monohydrate (see Section 2), sodium starch glycolate, talc, povidone, magnesium stearate, colloidal anhydrous silica.
  • Ingredients that coat the tablet: methacrylic acid-methyl methacrylate copolymer (1:2), talc, dibutyl sebacate, ferric oxide red (E172), methacrylic acid – methyl methacrylate copolymer (1:1), ferric oxide yellow (E172), macrogol.
  • Ingredients to label the medicine: propylene glycol, ferric oxide black (E172), ammonium hydroxide, shellac.

What Asacol 800mg MR tablets look like and contents of the pack

Asacol 800mg MR tablets are red-brown, coated, and oblong shaped, marked with WC 800. They are packed in a plastic bottle with a child- resistant closure that contains cotton/silica gel moisture absorbing pouches. Asacol 800mg MR tablets are available in packs of 12, 36, 84 or 180 tablets (not all pack sizes may be marketed). Marketing Authorisation Holder AbbVie Ltd. Maidenhead SL6 4UB UK Tel: +44 (0) 1628 561 090 Manufacturer Forest Laboratories Ireland Limited Clonshaugh Business and Technology Park, Clonshaugh, Dublin 17, D17 E400, Ireland or Allergan Pharmaceuticals International Limited Clonshaugh Business & Technology Park, Dublin 17, D17 E400, Ireland Getting more advice about ulcerative colitis or Crohn's ileo-colitis In addition to advice and information available from your doctor and pharmacist, you may wish to contact Crohn's and Colitis UK for Colitis and Crohn's Disease which offers information, advice and local support groups. Crohn's and Colitis UK, 1 Bishops Square (Helios Court), Hatfield Business Park, Hatfield, AL10 9NE Telephone Information Line: 01727 830038 Monday-Friday: 9am-5pm (except English bank holidays) Crohn's and Colitis Support Line: 0300 222 5700 Monday-Friday: 9am-5pm (except English bank holidays) To listen to or request a copy of this leaflet in Braille, large print or audio, please contact the Marketing Authorisation Holder. Asacol® is a Trademark This leaflet was last revised in January 2025

Frequently asked questions about Asacol 800mg MR Tablets

How do I take Asacol 800mg MR Tablets?

Asacol 800mg MR Tablets comes as tablet containing 800mg. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.

What is the active substance in Asacol 800mg MR Tablets?

The active substance in Asacol 800mg MR Tablets is mesalazine.

Are there equivalent medicines to Asacol 800mg MR Tablets?

Medicines with the same active substance, strength and form include: Octasa 800 mg modified-release tablets. They are interchangeable only if your prescriber or pharmacist says so.

Where does this information come from?

This leaflet reproduces the patient information leaflet approved for Asacol 800mg MR Tablets, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.

Can I get Asacol 800mg MR Tablets without a prescription?

Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.

About this leaflet

The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.

Medical disclaimer: This page is for information only and does not replace advice from your doctor or pharmacist. Always read the leaflet supplied with your medicine. If you are unwell, call NHS 111; in an emergency, call 999.

Medicines with the same active substance: Mesalazine (31 medicines)
See every medicine containing this substance, or browse the full A–Z of active substances.
⚕For healthcare professionals — Summary of Product Characteristics (SmPC)Full SmPC: dosage, interactions, contraindications, warnings+
Technical information intended for healthcare professionals (doctors and pharmacists). The Summary of Product Characteristics (SmPC) is the official document approved by the MHRA/EMA. It does not replace the patient leaflet or a doctor’s advice.

4.1. Therapeutic indications

Ulcerative colitis: For the treatment of mild to moderate acute exacerbations. For the maintenance of remission.

Crohn's ileo-colitis: For the maintenance of remission.

4.2. Posology and method of administration

Swallow whole with water. Do not break, crush or chew the tablets before swallowing.

ADULTS:

Mild acute exacerbations of ulcerative colitis: Three tablets (2.4g) a day in divided doses.

Moderate acute exacerbations of ulcerative colitis: Six tablets (4.8g) a day in divided doses.

Maintenance of remission of ulcerative colitis: Up to three tablets (2.4g) a day once daily or in divided doses.

Maintenance of remission of Crohn's ileocolitis: Up to three tablets (2.4g) a day in divided doses.

ELDERLY: The normal adult dosage may be used unless renal function is impaired (see section 4.4).

CHILDREN: Not recommended.

4.3. Contraindications

A history of sensitivity to salicylates or any of the ingredients; renal sensitivity to sulfasalazine. Confirmed severe renal impairment (GFR less than 20 ml/min). Severe hepatic impairment. Gastric or duodenal ulcer, haemorrhagic tendency.

4.4. Special warnings and precautions for use

Geriatric Use

Use in the elderly should be cautious and subject to patients having normal renal function.

Intolerance

Mesalazine inhibits the thiopurine methyl-transferase (TPMT) activity in vitro and may therefore impair the metabolism of azathioprine, thioguanine and 6-mercaptopurine. Standard haematological indices (including the white cell count) should be monitored repeatedly in patients taking azathioprine, especially at the beginning of such combination therapy, whether or not mesalazine is prescribed.

Mesalazine has been implicated in the production of an acute intolerance syndrome characterized by cramping, acute abdominal pain and bloody diarrhoea, sometimes fever, headache and a rash; in such cases prompt withdrawal is required. The patient's history of sulfasalazine intolerance, if any, should be re-evaluated. If a rechallenge is performed later in order to validate the hypersensitivity, it should be carried out under close supervision and only if clearly needed, giving consideration to reduced dosage. The possibility of increased absorption of mesalazine and concomitant renal tubular damage as noted in the preclinical studies must be kept in mind. Patients on mesalazine 1000 mg, especially those on concurrent oral products which contain or release mesalazine and those with pre-existing renal disease, should be carefully monitored with urinalysis, BUN and creatinine testing.

Renal disorders

Mesalazine may produce red-brown urine discoloration after contact with sodium hypochlorite bleach (e.g., in toilets cleaned with sodium hypochlorite contained in certain bleaches).

Mesalazine is excreted rapidly by the kidney, mainly as its metabolite, N-acetyl-5-aminosalicylic acid. In rats, large doses of mesalazine injected intravenously produce tubular and glomerular toxicity. Asacol should be used with extreme caution in patients with confirmed mild to moderate renal impairment (see section 4.3). Patients on mesalazine should have renal function monitored, (with serum creatinine levels measured) prior to treatment start. Renal function should then be monitored periodically during treatment, for example every 3 months for the first year, then every 6 months for the next 4 years and annually thereafter, based on individual patient history. Physicians should take into account risk factors such as prior and concomitant medications, duration and severity of disease and concurrent illnesses. Mesalazine-induced nephrotoxicity should be suspected in patients developing renal dysfunction during treatment. Treatment with mesalazine should be discontinued if renal function deteriorates. If dehydration develops, normal electrolyte and fluid balance should be restored as soon as possible.

Nephrolithiasis

Cases of nephrolithiasis have been reported with the use of mesalazine, including stones of 100% mesalazine content. It is recommended to ensure adequate fluid intake during treatment.

Hepatic Failure

There have been reports of hepatic failure in patients with pre-existing liver disease who have been administered mesalazine. Evaluate the risk and benefits of using mesalazine in patients with known liver impairment.

Blood Dyscrasias

Serious blood dyscrasias (some with fatal outcome) have been reported very rarely with mesalazine. Haematological investigations including a complete blood count may be performed prior to initiation and whilst on therapy according to the physician's judgement. Such tests should be done immediately if the patient develops unexplained bleeding, bruising, purpura, anaemia, fever or sore throat. Treatment should be stopped if there is suspicion or evidence of blood dyscrasia.

Severe cutaneous adverse reactions

Severe cutaneous adverse reactions (SCARs), including Drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), have been reported in association with mesalazine treatment.

Mesalazine should be discontinued, at the first appearance of signs and symptoms of severe skin reactions, such as skin rash, mucosal lesions, or any other sign of hypersensitivity.

Sensitivity/Hypersensitivity

Caution should be exercised when mesalazine (5-ASA) is initially used in patients known to be allergic to sulfasalazine. These patients should be instructed to discontinue therapy if signs of rash or fever become apparent. In case of an allergic reaction, appropriate measures (standard of care) should be taken.

Cardiac hypersensitivity reactions

Mesalazine-induced cardiac hypersensitivity reactions (myo- and pericarditis) have rarely been reported with mesalazine containing products. In case of previous mesalazine-induced cardiac hypersensitivity Asacol must not be reintroduced. Caution should be taken in patients with previous myo- or pericarditis of allergic background regardless of its origin.

Pulmonary disease

Patients with pulmonary disease, in particular asthma, should be very carefully monitored during treatment.

Idiopathic intracranial hypertension

Idiopathic intracranial hypertension (pseudotumor cerebri) has been reported in patients receiving mesalazine. Patients should be warned for signs and symptoms of idiopathic intracranial hypertension, including severe or recurrent headache, visual disturbances or tinnitus. If idiopathic intracranial hypertension occurs, discontinuation of mesalazine should be considered.

Excipients with known effect warnings

Lactose

With reference to the presence of lactose monohydrate in the formulation, patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.

Sodium content

This medicine contains less than 1 mmol sodium (23 mg) per dosage unit, i.e. is essentially "sodium-free".

4.5. Interaction with other medicinal products and other forms of interaction

'Asacol' tablets should not be given with lactulose or similar preparations, which lower stool pH and may prevent release of mesalazine.

Concurrent use of other known nephrotoxic agents, such as NSAIDs and azathioprine, may increase the risk of renal reactions (see section 4.4).

Monitor patients taking nephrotoxic drugs for changes in renal function and mesalazine-related adverse reactions.

The hypoglycaemic effect of sulfonylureas may be enhanced when administered with aminosalicylates (oral antidiabetics may be displaced from the binding sites of plasma proteins). 5- ASA was reported to inhibit coumarin anticoagulants, resulting in thrombosis.

Concomitant treatment with mesalazine may increase the risk of myelosuppression in patients receiving azathioprine, thioguanine or 6-mercaptopurine. The concurrent use of mesalazine with azathioprine, thioguanine or 6-mercaptopurine may increase the risk for blood dyscrasia. If concomitant use of mesalazine and azathioprine, thioguanine or 6-mercaptopurine cannot be avoided, monitor blood tests, including complete blood cell counts and platelet counts.

Several reports of possible interference with measurements, by liquid chromatography, of urinary normetanephrine have been observed in patients exposed to sulfasalazine or its metabolite, mesalazine.

4.6. Fertility, pregnancy and lactation

Pregnancy

Mesalazine is known to cross the placental barrier, but the limited data available on its use in pregnant women do not allow accurate assessment of possible adverse effects.

Mesalazine should therefore be used with caution during pregnancy and lactation when the potential benefit outweighs the possible hazards in the opinion of the physician.

Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, parturition or postnatal development (see section 5.3).

Lactation

Low concentrations of mesalazine and higher concentrations of its N-acetyl metabolite have been detected in human milk. While the clinical significance of this has not been determined, caution should be exercised when mesalazine is administered to a nursing woman. Hypersensitivity reactions like diarrhoea cannot be excluded. If the infant develops diarrhoea breastfeeding should be discontinued.

4.7. Effects on ability to drive and use machines

There are no data available on the effects of mesalazine on ability to drive and use machines.

4.8. Undesirable effects

In Phase III clinical studies in patients with moderate active ulcerative colitis, treated for 6 weeks with either 2.4g/day or 4.8g/day, there was no difference in the adverse event profiles between doses. The events are presented in the table below:

Adverse Events Reported in ≥ 2% of Patients in Either Treatment Group

Adverse Event*

Asacol 800 mg (4.8 g/day)

N = 213 (%)

Mesalazine 400 mg (2.4 g/day)

N = 235 (%)

Headache

16 (7.5%)

14 (6.0%)

Abdominal pain

9 (4.2%)

12 (5.1%)

Diarrhoea

8 (3.8%)

9 (3.8%)

Nausea

8 (3.8%)

4 (1.7%)

Respiratory infection

7 (3.3%)

4 (1.7%)

Exacerbation of colitis

6 (2.8%)

6 (2.6%)

Dyspepsia

6 (2.8%)

5 (2.1%)

Vomiting

6 (2.8%)

2 (0.9%)

Flatulence

5 (2.3%)

7 (3.0%)

Rectal disorder

4 (1.9%)

6 (2.6%)

Flu syndrome

3 (1.4%)

8 (3.4%)

Rash

3 (1.4%)

5 (2.1%)

Increased cough

1 (0.5%)

9 (3.8%)

Sinusitis

1 (0.5%)

5 (2.1%)

Rhinitis

0 (0.0%)

7 (3.0%)

*Adverse events are listed by decreasing frequency as observed in the 4.8 g/day treatment group

Adverse events seen with oral mesalazine products are predominantly gastrointestinal, including nausea, vomiting, diarrhoea, and abdominal pain. Headache and arthralgia/myalgia have also been reported.

Undesirable effects reported from clinical studies and post marketing surveillance are listed below. Common, (≥1/100 to <1/10), uncommon (≥ 1/1,000 to <1/100), rare (≥ 1/10,000 to <1/1,000), very rare (< 1/10,000), frequency not known (cannot be estimated from the available data).

System organ class

Common

(≥ 1/100 to < 1/10)

Uncommon

(≥ 1/1,000 to <1/100)

Rare

(≥ 1/10,000 to < 1/1,000)

Very rare

(< 1/10,000)

Frequency not Known

Blood and lymphatic system disorders

leucopenia,

neutropenia,

agranulocytosis,

aplastic anaemia and thrombocytopenia*

Immune system disorders

hypersensitivity reactions*

Nervous system disorders

headache

peripheral neuropathy,

vertigo

Idiopathic intracranial hypertension*

Cardiac disorders

myocarditis,

pericarditis*

Respiratory thoracic and mediastinal disorders

bronchospasm,

eosinophilic pneumonia

interstitial pneumonitis

Pleurisy, allergic and fibrotic lung reactions

Gastrointestinal disorders

nausea,

vomiting,

diarrhoea,

abdominal pain

pancreatitis

exacerbation of the symptoms of colitis

Constipation

Hepato-biliary disorders

abnormalities of hepatic function (including hepatic failure) / abnormal liver function test, hepatitis

Skin and subcutaneous tissue disorders

alopecia, lupus erythematosus-like reactions, rash (including urticaria), bullous skin reactions

erythema multiforme

Drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN)*

Musculoskeletal connective tissue and bone disorders

arthralgia/ myalgia

Renal and urinary disorders

interstitial nephritis and nephrotic syndrome.

Renal failure.*

nephrolithiasis*

Reproductive system and breast disorders

oligospermia (reversible)

General disorders and administration site conditions:

Drug fever

mesalazine-induced acute intolerance syndrome*

* See Section 4.4 for further information

Severe cutaneous adverse reactions (SCARs), including Drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), have been reported in association with mesalazine treatment (see section 4.4).

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard

4.9. Overdose

There have been no documented reports of serious toxicity in human resulting from massive overdosing with mesalazine. Under ordinary circumstances, mesalazine absorption from the colon is limited. Mesalazine is not metabolized to salicylate. There is no specific antidote for mesalazine overdose and treatment is symptomatic and supportive. It may include intravenous infusion of appropriate electrolytes.

💬 Ask about this leaflet

Ask anything about Asacol 800mg MR Tablets. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.

Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.

Pharmacies in major towns and cities — see the list
Pharmacies by county and region — see the full list

Browse all 2,009 towns and cities →